<?xml version="1.0" encoding="UTF-8"?><section ID="ID_1fc299ae-dcae-4e1b-aa72-2fcb54f2f159">
<id root="3f931744-9d36-4064-82ab-ad3f48827178"/>
<code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
<title>5 WARNINGS AND PRECAUTIONS</title>
<effectiveTime value="20191011"/>
<excerpt>
<highlight>
<text>
<list listType="unordered">
<item>
<caption>•</caption>
<content styleCode="underline">Localized Infections:</content> Candida albicans infection of the mouth and throat may occur. Monitor patients periodically for signs of adverse effects on the oral cavity. Advise patients to rinse the mouth following inhalation (<linkHtml href="#nelsonjk1279119355555">5.1</linkHtml>)</item>
<item>
<caption>•</caption>
<content styleCode="underline">Deterioration of Disease and Acute Asthma Episodes:</content> Do not use for the relief of acute bronchospasm (<linkHtml href="#nelsonjk1279120044261">5.2</linkHtml>)</item>
<item>
<caption>•</caption>
<content styleCode="underline">Hypersensitivity Reactions:</content> Anaphylaxis, rash, contact dermatitis, urticaria, angioedema, and bronchospasm have been reported with use of PULMICORT RESPULES. Discontinue PULMICORT RESPULES if such reactions occur (<linkHtml href="#nelsonjk1279119388961">5.3</linkHtml>)</item>
<item>
<caption>•</caption>
<content styleCode="underline">Immunosuppression:</content> Potential worsening of infections (e.g., existing tuberculosis, fungal, bacterial, viral, or parasitic infection; or ocular herpes simplex). Use with caution in patients with these infections. More serious or even fatal course of chickenpox or measles can occur in susceptible patients (<linkHtml href="#nelsonjk1279119412992">5.4</linkHtml>)</item>
<item>
<caption>•</caption>
<content styleCode="underline">Transferring Patients from Systemic Corticosteroid Therapy:</content> Risk of impaired adrenal function when transferring from oral steroids. Taper patients slowly from systemic corticosteroids if transferring to PULMICORT RESPULES (<linkHtml href="#nelsonjk1279119568739">5.5</linkHtml>)</item>
<item>
<caption>•</caption>
<content styleCode="underline">Hypercorticism and Adrenal Suppression:</content> May occur with very high dosages or at the regular dosage in susceptible individuals. If such changes occur, reduce PULMICORT RESPULES slowly (<linkHtml href="#nelsonjk1279119432632">5.6</linkHtml>)</item>
<item>
<caption>•</caption>
<content styleCode="underline">Reduction in Bone Mineral Density with Long-term Administration:</content> Monitor patients with major risk factors for decreased bone mineral content (<linkHtml href="#nelsonjk1279119451835">5.7</linkHtml>)</item>
<item>
<caption>•</caption>
<content styleCode="underline">Effects on Growth:</content> Monitor growth of pediatric patients (<linkHtml href="#nelsonjk1279067620485">5.8</linkHtml>)</item>
<item>
<caption>•</caption>
<content styleCode="underline">Glaucoma and Cataracts:</content> Close monitoring is warranted (<linkHtml href="#nelsonjk1279066943771">5.9</linkHtml>)</item>
<item>
<caption>•</caption>
<content styleCode="underline">Paradoxical Bronchospasm:</content> Discontinue PULMICORT RESPULES and institute alternative therapy if paradoxical bronchospasm occurs (<linkHtml href="#nelsonjk1279067463283">5.10</linkHtml>)</item>
<item>
<caption>•</caption>
<content styleCode="underline">Eosinophilic Conditions and Churg-Strauss Syndrome:</content> Be alert to eosinophilic conditions (<linkHtml href="#nelsonjk1279119544536">5.11</linkHtml>)</item>
</list>
</text>
</highlight>
</excerpt>
<component>
<section ID="nelsonjk1279119355555">
<id root="924afa14-ff07-4c1e-b4cc-ea06891cc3f7"/>
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
<title>5.1 Local Effects</title>
<text>
<paragraph>In clinical trials with PULMICORT RESPULES, localized infections with <content styleCode="italics">Candida albicans</content> occurred in the mouth and pharynx in some patients. The incidences of localized infections of <content styleCode="italics">Candida albicans</content> were similar between the placebo and PULMICORT RESPULES treatment groups. If these infections develop, they may require treatment with appropriate local or systemic antifungal therapy and/or discontinuance of treatment with PULMICORT RESPULES. Patients should rinse the mouth after inhalation of PULMICORT RESPULES.</paragraph>
</text>
<effectiveTime value="20161025"/>
</section>
</component>
<component>
<section ID="nelsonjk1279120044261">
<id root="7549a6ed-fe99-4873-ab9c-97f6ff8e6a95"/>
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
<title>5.2 Deterioration of Disease and Acute Asthma Episodes</title>
<text>
<paragraph>PULMICORT RESPULES is not a bronchodilator and is not indicated for the rapid relief of acute bronchospasm or other acute episodes of asthma.</paragraph>
<paragraph>Patients should be instructed to contact their physician immediately if episodes of asthma not responsive to their usual doses of bronchodilators occur during the course of treatment with PULMICORT RESPULES. During such episodes, patients may require therapy with oral corticosteroids.</paragraph>
</text>
<effectiveTime value="20161025"/>
</section>
</component>
<component>
<section ID="nelsonjk1279119388961">
<id root="ef7aaaaf-6e6d-4598-a7c3-dec14d27b7d7"/>
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
<title>5.3 Hypersensitivity Reactions Including Anaphylaxis</title>
<text>
<paragraph>Hypersensitivity reactions including anaphylaxis, rash, contact dermatitis, urticaria, angioedema, and bronchospasm have been reported with use of PULMICORT RESPULES. Discontinue PULMICORT RESPULES if such reactions occur <content styleCode="italics">[see <linkHtml href="#nelsonjk1279067428237">Contraindications (4)</linkHtml>].</content>
</paragraph>
</text>
<effectiveTime value="20161025"/>
</section>
</component>
<component>
<section ID="nelsonjk1279119412992">
<id root="6b54d43e-0156-4b0c-b1b0-4a12fe06c6ed"/>
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
<title>5.4 Immunosuppression</title>
<text>
<paragraph>Patients who are on drugs that suppress the immune system are more susceptible to infection than healthy individuals. Chicken pox and measles, for example, can have a more serious or even fatal course in susceptible children or adults using corticosteroids. In children or adults who have not had these diseases, or been properly immunized, particular care should be taken to avoid exposure. How the dose, route, and duration of corticosteroid administration affect the risk of developing a disseminated infection is not known. The contribution of the underlying disease and/or prior corticosteroid treatment to the risk is also not known. If exposed to chicken pox, therapy with varicella zoster immune globulin (VZIG) or pooled intravenous immunoglobulin (IVIG), as appropriate, may be indicated. If exposed to measles, prophylaxis with pooled intramuscular immunoglobulin (IG) may be indicated (see the respective package inserts for complete VZIG and IG prescribing information). If chicken pox develops, treatment with antiviral agents may be considered.</paragraph>
<paragraph>The clinical course of chicken pox or measles infection in patients on inhaled corticosteroids has not been studied. However, a clinical study has examined the immune responsiveness of asthma patients 12 months to 8 years of age who were treated with PULMICORT RESPULES. An open-label non-randomized clinical study examined the immune responsiveness of varicella vaccine in 243 asthma patients 12 months to 8 years of age who were treated with PULMICORT RESPULES 0.25 mg to 1 mg daily (n=151) or non-corticosteroid asthma therapy (n=92) (i.e., beta<sub>2</sub>-agonists, leukotriene receptor antagonists, cromones). The percentage of patients developing a seroprotective antibody titer of ≥5.0 (gpELISA value) in response to the vaccination was similar in patients treated with PULMICORT RESPULES (85%) compared to patients treated with non-corticosteroid asthma therapy (90%). No patient treated with PULMICORT RESPULES developed chicken pox as a result of vaccination. </paragraph>
<paragraph>Inhaled corticosteroids should be used with caution, if at all, in patients with active or quiescent tuberculosis infection of the respiratory tract, untreated systemic fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex.</paragraph>
</text>
<effectiveTime value="20190906"/>
</section>
</component>
<component>
<section ID="nelsonjk1279119568739">
<id root="ddd76e7b-888e-44da-97cf-b6518b5ccbfe"/>
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
<title>5.5 Transferring Patients from Systemic Corticosteroid Therapy</title>
<text>
<paragraph>Particular care is needed for patients who are transferred from systemically active corticosteroids to inhaled corticosteroids because deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids to less systemically available inhaled corticosteroids. After withdrawal from systemic corticosteroids, a number of months are required for recovery of hypothalamic-pituitary-adrenal (HPA)-axis function. </paragraph>
<paragraph>Patients who have been previously maintained on 20 mg or more per day of prednisone (or its equivalent) may be most susceptible, particularly when their systemic corticosteroids have been almost completely withdrawn. </paragraph>
<paragraph>During this period of HPA-axis suppression, patients may exhibit signs and symptoms of adrenal insufficiency when exposed to trauma, surgery, infection (particularly gastroenteritis) or other conditions associated with severe electrolyte loss. Although PULMICORT RESPULES may provide control of asthma symptoms during these episodes, in recommended doses it supplies less than normal physiological amounts of glucocorticosteroid systemically and does NOT provide the mineralocorticoid activity that is necessary for coping with these emergencies.</paragraph>
<paragraph>During periods of stress or a severe asthma attack, patients who have been withdrawn from systemic corticosteroids should be instructed to resume oral corticosteroids (in large doses) immediately and to contact their physicians for further instructions. These patients should also be instructed to carry a medical identification card indicating that they may need supplementary systemic corticosteroids during periods of stress or a severe asthma attack.</paragraph>
<paragraph>Patients requiring oral corticosteroids should be weaned slowly from systemic corticosteroid use after transferring to PULMICORT RESPULES. Initially, PULMICORT RESPULES should be used concurrently with the patient’s usual maintenance dose of systemic corticosteroid. After approximately one week, gradual withdrawal of the systemic corticosteroid may be initiated by reducing the daily or alternate daily dose. Further incremental reductions may be made after an interval of one or two weeks, depending on the response of the patient. Generally, these decrements should not exceed 25% of the prednisone dose or its equivalent. A slow rate of withdrawal is strongly recommended.</paragraph>
<paragraph>Lung function (FEV<sub>1</sub> or AM PEF), beta-agonist use, and asthma symptoms should be carefully monitored during withdrawal of oral corticosteroids. In addition to monitoring asthma signs and symptoms, patients should be observed for signs and symptoms of adrenal insufficiency such as fatigue, lassitude, weakness, nausea and vomiting, and hypotension. </paragraph>
<paragraph>Transfer of patients from systemic corticosteroid therapy to PULMICORT RESPULES may unmask allergic or other immunologic conditions previously suppressed by the systemic corticosteroid therapy, e.g., rhinitis, conjunctivitis, eosinophilic conditions, eczema, and arthritis <content styleCode="italics">[see <linkHtml href="#nelsonjk1279119223667">Dosage and Administration (2)</linkHtml>]</content>.</paragraph>
<paragraph>During withdrawal from oral corticosteroids, patients may experience symptoms of systemically active corticosteroid withdrawal (e.g., joint and/or muscular pain, lassitude, depression) despite maintenance or even improvement of respiratory function.</paragraph>
</text>
<effectiveTime value="20161025"/>
</section>
</component>
<component>
<section ID="nelsonjk1279119432632">
<id root="5231102e-f036-4287-996b-e635a20efa94"/>
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
<title>5.6 Hypercorticism and Adrenal Suppression</title>
<text>
<paragraph>PULMICORT RESPULES, will often help control asthma symptoms with less suppression of HPA function than therapeutically equivalent oral doses of prednisone. Since individual sensitivity to effects on cortisol production exists, physicians should consider this information when prescribing PULMICORT RESPULES. Because of the possibility of systemic absorption of inhaled corticosteroids, patients treated with PULMICORT RESPULES should be observed carefully for any evidence of systemic corticosteroid effects. Particular care should be taken in observing patients post-operatively or during periods of stress for evidence of inadequate adrenal response. It is possible that systemic corticosteroid effects such as hypercorticism, and adrenal suppression (including adrenal crisis) may appear in a small number of patients, particularly when budesonide is administered at higher than recommended doses over prolonged periods of time. If such effects occur, the dosage of PULMICORT RESPULES should be reduced slowly, consistent with accepted procedures for tapering of systemic corticosteroids and for management of asthma.</paragraph>
</text>
<effectiveTime value="20161025"/>
</section>
</component>
<component>
<section ID="nelsonjk1279119451835">
<id root="2da57046-56a3-4465-9c03-41931610feab"/>
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
<title>5.7 Reduction in Bone Mineral Density</title>
<text>
<paragraph>Decreases in bone mineral density (BMD) have been observed with long-term administration of products containing inhaled corticosteroids. The clinical significance of small changes in BMD with regard to long-term outcomes is unknown. Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants and corticosteroids), should be monitored and treated with established standards of care.</paragraph>
</text>
<effectiveTime value="20161025"/>
</section>
</component>
<component>
<section ID="nelsonjk1279067620485">
<id root="725ff31e-0cb5-4313-91ba-01655be2d680"/>
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
<title>5.8 Effects on Growth</title>
<text>
<paragraph>Orally inhaled corticosteroids, including budesonide, may cause a reduction in growth velocity when administered to pediatric patients. Monitor the growth of pediatric patients receiving PULMICORT RESPULES routinely (e.g., via stadiometry). To minimize the systemic effects of orally inhaled corticosteroids, including PULMICORT RESPULES, each patient should be titrated to his/her lowest effective dose <content styleCode="italics">[see </content>
<content styleCode="italics">
<linkHtml href="#nelsonjk1279067656532">Use in Specific Populations (8.4)</linkHtml>
</content>
<content styleCode="italics">]</content>.</paragraph>
</text>
<effectiveTime value="20161025"/>
</section>
</component>
<component>
<section ID="nelsonjk1279066943771">
<id root="691d628b-9c82-49ca-8fb3-5c5001780d12"/>
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
<title>5.9 Glaucoma and Cataracts</title>
<text>
<paragraph>Glaucoma, increased intraocular pressure, and cataracts have been reported following the long-term administration of inhaled corticosteroids, including budesonide. Therefore, close monitoring is warranted in patients with a change in vision or with a history of increased intraocular pressure, glaucoma, and/or cataracts.</paragraph>
</text>
<effectiveTime value="20161025"/>
</section>
</component>
<component>
<section ID="nelsonjk1279067463283">
<id root="3f27e865-c22b-4fad-8606-39d3bbc39b4e"/>
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
<title>5.10 Paradoxical Bronchospasm and Upper Airway Symptoms</title>
<text>
<paragraph>As with other inhaled asthma medications, bronchospasm, with an immediate increase in wheezing, may occur after dosing. If acute bronchospasm occurs following dosing with PULMICORT RESPULES, it should be treated immediately with a fast-acting inhaled bronchodilator. Treatment with PULMICORT RESPULES should be discontinued and alternate therapy instituted. </paragraph>
</text>
<effectiveTime value="20161025"/>
</section>
</component>
<component>
<section ID="nelsonjk1279119544536">
<id root="2fdb188c-4b37-44f4-b997-6fa5f2b843dc"/>
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
<title>5.11 Eosinophilic Conditions and Churg-Strauss Syndrome</title>
<text>
<paragraph>In rare cases, patients on inhaled corticosteroids may present with systemic eosinophilic conditions. Some of these patients have clinical features of vasculitis consistent with Churg-Strauss syndrome, a condition that is often treated with systemic corticosteroids therapy. These events usually, but not always, have been associated with the reduction and/or withdrawal of oral corticosteroid therapy following the introduction of inhaled corticosteroids. Healthcare providers should be alert to eosinophilia, vasculitis rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients. A causal relationship between budesonide and these underlying conditions has not been established.</paragraph>
</text>
<effectiveTime value="20161025"/>
</section>
</component>
<component>
<section ID="nelsonjk1279119598129">
<id root="c6ac6b18-8729-4c49-a713-fd16143ce67b"/>
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
<title>5.12 Drug Interactions with Strong Cytochrome P450 3A4 Inhibitors</title>
<text>
<paragraph>Caution should be exercised when considering the coadministration of PULMICORT RESPULES with ketoconazole, and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) because adverse effects related to increased systemic exposure to budesonide may occur <content styleCode="italics">[see <linkHtml href="#nelsonjk1279119306431">Drug Interactions (7.1)</linkHtml>, </content>
<content styleCode="italics">
<linkHtml href="#nelsonjk1279119335993">Clinical Pharmacology (12.3)</linkHtml>
</content>
<content styleCode="italics">]</content>.</paragraph>
</text>
<effectiveTime value="20161025"/>
</section>
</component>
</section>
What is an AstraZeneca authorized person?This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
